ArticleAnnals of surgical oncology2022
A Single-Center Study of Adherence to Breast Cancer Screening Mammography Guidelines by Transgender and Non-Binary Patients.
Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cancer screening attendance rates in transgender and gender-diverse patients: a systematic review and meta-analysis.BMJ evidence-based medicine · 2024Pooled it
- Training imaging professionals on transgender-inclusive breast cancer screening practices.Cancer causes & control : CCC · 2026Article
- Healthcare professional perspectives on hereditary breast cancer risk assessment prior to gender-affirming mastectomy.Breast cancer research and treatment · 2026Article
- Characteristics of Gender-Diverse Patients With Breast Cancer.JAMA network open · 2026Article
- Breast Cancer Disparities in the LGBTQ + Community: How to Move Towards Inclusive Care from Screening to Survivorship.Current breast cancer reports · 2025Article
- Transgender and Gender-Diverse Patient Perspectives on Hereditary Breast Cancer Risk Assessment in Gender-Affirming Top Surgeries.JCO precision oncology · 2025Article
- Oncological needs in transgender patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- A Scoping Review Mapping Trans* and Gender Diverse People's Representation in Cancer Research.Cancer medicine · 2025Article
- Targeted intervention and monitoring of sex assigned at birth, sexual orientation, and gender identity data scale-up: the intersection of research, policy, and patient care.Journal of the National Cancer Institute. Monographs · 2025Article
- Evaluation of the Current Knowledge Base of Breast Cancer Screening Recommendations in the Transgender Population at an Academic Medical Center.Journal of community health · 2025Article
- Educational Initiatives to Improve the Cancer-Related Disparities Facing Transgender and Gender Diverse (TGD) Individuals.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Article
- Influence of gender modality on the delivery of breast cancer care from diagnosis to treatment: A systematic review.International journal of transgender health · 2025Review
- Early detection of cervical and breast cancer in transgender and allogender individuals assigned female at birth: A scoping review.International journal of transgender health · 2025Review
- Sociodemographic profile, health-related behaviours and experiences of healthcare access in Italian transgender and gender diverse adult population.Journal of endocrinological investigation · 2024Article
- The Impact of a Breast Cancer Risk Assessment on the Decision for Gender-Affirming Chest Masculinization Surgery in Transgender and Gender-Diverse Individuals: A Pilot Single-Arm Educational Intervention Trial.Annals of surgical oncology · 2024Observational
- Automated system utilizing non-invasive technique mammograms for breast cancer detection.BMC medical imaging · 2024Article
- Breast and cervical cancer screenings across gender identity: results from the Behavioral Risk Factor Surveillance System before and during the COVID-19 pandemic.Cancer causes & control : CCC · 2024Article
- Breast cancer and gender-affirming hormone therapy for transgender and gender-diverse (TGD) individuals.Maturitas · 2024Review
- Prevalence and predictors of cancer screening in transgender and gender nonbinary individuals.International journal of transgender health · 2024Article
- Cancer surveillance for transgender and gender diverse patients with Lynch syndrome: a practice resource of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer.Familial cancer · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdherence to screening guidelines among transgender and non-binary (TGNB) populations is not well studied. This study examines breast cancer screening patterns among TGNB patients at an urban academic medical center.
methodsDemographic information, risk factors, and screening mammography were collected. Mammography rates were calculated in populations of interest according to national guidelines, and mammogram person-years were also calculated. Univariate and multivariate logistic regression was performed.
resultsOverall, 253 patients were analyzed: 193 transgender women and non-binary people designated male at birth (TGNB DMAB) and 60 transgender men and non-binary people designated female at birth (TGNB DFAB). The median (interquartile range) age was 53.2 years (42.3-62.6). Most patients had no family history of breast cancer (n = 163, 64.4%) and were on hormone therapy (n = 191, 75.5%). Most patients where White (n = 164, 64.8%), employed (n = 113, 44.7%), and had public insurance (n = 128, 50.6%). TGNB DFAB breast screening rates were low, ranging from 2.0 to 50.0%, as were TGNB DMAB screening rates, ranging from 7.1 to 47.6%. The screening rates among the TGNB DFAB and TGNB DMAB groups did not significantly differ from one another. Among TGNB DFAB patients, univariate analyses showed no significant predictors for mammography. Among TGNB DMAB patients, not being on hormone therapy resulted in fewer odds of undergoing mammography. There were no significant findings on multivariate analyses.
conclusionMammography rates in the TGNB population are lower than institutional and national rates for cisgender patients, which are 77.3% and 66.7-78.4%, respectively. Stage of transition, organs present, hormone therapy, and risk factors should be considered to guide screening.
Indexed as
Identifiers
34704183What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.